약물전달 공동 연구 및 라이선싱 계약(2019-2025년)

Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the drug delivery deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of drug delivery deals from 2019 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1246 drug delivery deals announced since 2019 including financial terms where available including links to online deal records of actual drug delivery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of drug delivery dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in drug delivery dealmaking since 2019.

Chapter 3 provides an overview of the leading drug delivery deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in drug delivery dealmaking with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of drug delivery deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since Jan 2019. The chapter is organized by specific drug delivery technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in drug delivery deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Drug Delivery Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse drug delivery collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Drug Delivery Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of drug delivery trends and structure of deals entered into by leading biopharma companies worldwide.

Drug Delivery Collaboration and Licensing Deals includes:

• Trends in drug delivery dealmaking in the biopharma industry
• Directory of drug delivery deal records covering pharmaceutical and biotechnology
• The leading drug delivery deals by value
• Most active drug delivery licensing dealmakers
• Drug Delivery Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

• 2.1. Introduction
• 2.2. Drug delivery deals over the years
• 2.3. Most active drug delivery dealmakers
• 2.4. Drug delivery deals by deal type
• 2.5. Drug delivery deals by therapy area
• 2.6. Drug delivery deals by industry sector
• 2.7. Deal terms for drug delivery deals
  • 2.7.1 Drug delivery deals headline values
  • 2.7.2 Drug delivery deal upfront payments
  • 2.7.3 Drug delivery deal milestone payments
  • 2.7.4 Drug delivery royalty rates

Chapter 3 - Leading drug delivery deals

• 3.1. Introduction
• 3.2. Top drug delivery deals by value

Chapter 4 - Most active drug delivery dealmakers

• 4.1. Introduction
• 4.2. Most active drug delivery dealmakers
• 4.3. Most active drug delivery deals company profiles

Chapter 5 - Drug delivery contracts dealmaking directory

• 5.1. Introduction
• 5.2. Drug delivery contracts dealmaking directory

Chapter 6 - Drug delivery dealmaking by technology type

• Deal directory
• Deal directory - Drug delivery deals by company A-Z
• Deal directory - Drug delivery deals by deal type
• Deal directory - Drug delivery deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Drug delivery deals since 2019
• Figure 2: Active drug delivery dealmaking activity - 2019 - 2025
• Figure 3: Drug delivery deals by deal type since 2019
• Figure 4: Drug delivery deals by therapy area since 2019
• Figure 5: Drug delivery deals by industry sector since 2019
• Figure 6: Drug delivery deals with a headline value
• Figure 7: Drug delivery deals with an upfront value
• Figure 8: Drug delivery deals with a milestone value
• Figure 9: Drug delivery deals with a royalty rate value
• Figure 10: Top drug delivery deals by value since 2019
• Figure 11: Most active drug delivery dealmakers 2019 - 2025
• Figure 12: Drug delivery deals by technology type since 2019